Unique ID issued by UMIN | UMIN000001681 |
---|---|
Receipt number | R000002029 |
Scientific Title | The medical economic effects of the Pneumococcal vaccine in the elderly. |
Date of disclosure of the study information | 2009/03/01 |
Last modified on | 2012/08/02 17:15:32 |
The medical economic effects of the Pneumococcal vaccine in the elderly.
Pneumococcal vaccination in the elderly.
The medical economic effects of the Pneumococcal vaccine in the elderly.
Pneumococcal vaccination in the elderly.
Japan |
Community-acquired pneumonia in the elderly
Pneumology | Geriatrics |
Others
NO
Pneumonia is the leading cause of death in the elderly people. Pneumococcal pneumonia infection is about 20 to 30 percent of the causes of pneumonia in the elderly. The pneumococcal vaccine is known to reduce deaths from pneumococcal infection in the elderly and patients with chronic obstructive pulmonary disease (COPD). Based on these findings, pneumococcal vaccination is recommended in the United States and Europe. However, because of the insufficient evidence of the effectiveness of domestic and economic effects of the pneumococcal vaccine in Japan, the rate of pneumonia vaccination is low in the Japanese elderly.
The aim of this study is to clarify the effect of prevention of recurrent pneumonia in elderly patients with Pneumococcal vaccine.
Efficacy
Confirmatory
Explanatory
Not applicable
Incidence of pneumonia
Medical costs
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
No treatment
YES
NO
Institution is not considered as adjustment factor.
NO
Numbered container method
2
Prevention
Vaccine |
Pneumococcal vaccination
without Pneumococcal vaccination
65 | years-old | <= |
90 | years-old | >= |
Male and Female
Patients who understand the purpose of this study and give informed consent.
1) patients who have already received Pneumococcal vaccine.
2) patients who are receiving radiation therapy
3) patients who are given an immunosuppressive drug
4) patients who have fever
5) patients with a malignant neoplasm
6) patients with a severe disease in liver, kidney, heart, or lung
7) when the doctor decides the patient's condition is inappropriate
200
1st name | |
Middle name | |
Last name | Mutsuo YAMAYA |
Tohoku University School of Medicine
Department of Advanced Preventive Medicine for Infectious Disease
2-1 Seiryoumachi, Aobaku, Sendai, JAPAN
022-717-7184
1st name | |
Middle name | |
Last name | Hiroshi KUBO |
Tohoku University School of Medicine
Department of Advanced Preventive Medicine for Infectious Disease
2-1 Seiryoumachi, Aobaku, Sendai, JAPAN
022-717-7184
hkubo@m.tains.tohoku.ac.jp
Department of Advanced Preventive Medicine for Infectious Disease, Tohoku University School of Medicine
Scholarship donation
Self funding
JAPAN
NO
2009 | Year | 03 | Month | 01 | Day |
Unpublished
Completed
2009 | Year | 02 | Month | 28 | Day |
2009 | Year | 05 | Month | 01 | Day |
2011 | Year | 01 | Month | 01 | Day |
2009 | Year | 02 | Month | 02 | Day |
2012 | Year | 08 | Month | 02 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002029
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |